OBJECTIVES: We sought to evaluate the impact of mixed aortic stenosis (MAS) on postprocedural aortic regurgitation (PPAR) and clinical outcomes after transcatheter aortic valve implantation (TAVI). BACKGROUND: The impact of MAS of TAVI outcomes is unknown. METHODS AND RESULTS: Data from a multicenter registry were retrospectively analysed. Outcomes were compared between patients with pure aortic stenosis (PAS; associated AR<1+/3+) and MAS (associated AR≥1+/3+). Study objectives were PPAR incidence and short- and long-term mortality. Overall, 1,062 patients were included: 419 (39.4%) with MAS and 643 (60.5%) with PAS. At 30 days, there were no differences in mortality, however, a higher incidence of major bleeding (22.7% vs. 16.8%; P=0.016), PPAR≥1+/3+ (42.6% vs. 26.5%; P<0.001) and lower device success (89.3% vs. 93.3%; P=0.019) was observed in patients with MAS. Of note, MAS was an independent predictor of PPAR≥1+/3+ at multivariable analysis (OR: 2.882; CI: 1.851-4.488; P<0.001). At 2 years of follow-up, no survival differences were present between MAS and PAS groups. Similarly, following stratification for PPAR≥1+/3+, MAS had no protective effect on survival as compared with PAS. CONCLUSIONS: MAS was associated with lower device success and higher PPAR incidence. However, despite these findings, it had no influence on long-term postoperative outcomes.
OBJECTIVES: We sought to evaluate the impact of mixed aortic stenosis (MAS) on postprocedural aortic regurgitation (PPAR) and clinical outcomes after transcatheter aortic valve implantation (TAVI). BACKGROUND: The impact of MAS of TAVI outcomes is unknown. METHODS AND RESULTS: Data from a multicenter registry were retrospectively analysed. Outcomes were compared between patients with pure aortic stenosis (PAS; associated AR<1+/3+) and MAS (associated AR≥1+/3+). Study objectives were PPAR incidence and short- and long-term mortality. Overall, 1,062 patients were included: 419 (39.4%) with MAS and 643 (60.5%) with PAS. At 30 days, there were no differences in mortality, however, a higher incidence of major bleeding (22.7% vs. 16.8%; P=0.016), PPAR≥1+/3+ (42.6% vs. 26.5%; P<0.001) and lower device success (89.3% vs. 93.3%; P=0.019) was observed in patients with MAS. Of note, MAS was an independent predictor of PPAR≥1+/3+ at multivariable analysis (OR: 2.882; CI: 1.851-4.488; P<0.001). At 2 years of follow-up, no survival differences were present between MAS and PAS groups. Similarly, following stratification for PPAR≥1+/3+, MAS had no protective effect on survival as compared with PAS. CONCLUSIONS: MAS was associated with lower device success and higher PPAR incidence. However, despite these findings, it had no influence on long-term postoperative outcomes.
Authors: Andrea Ungar; Giulio Mannarino; Nathalie van der Velde; Jan Baan; Marie-Pierre Thibodeau; Jean-Bernard Masson; Gennaro Santoro; Martijn van Mourik; Sofie Jansen; Cornelia Deutsch; Peter Bramlage; Jana Kurucova; Martin Thoenes; Stefania Maggi; Andreas W Schoenenberger Journal: BMC Cardiovasc Disord Date: 2018-01-04 Impact factor: 2.298
Authors: Zahra Keshavarz-Motamed; Seyedvahid Khodaei; Farhad Rikhtegar Nezami; Junedh M Amrute; Suk Joon Lee; Jonathan Brown; Eyal Ben-Assa; Tamara Garcia Camarero; Javier Ruano Calvo; Stephanie Sellers; Philipp Blanke; Jonathon Leipsic; Jose M de la Torre Hernandez; Elazer R Edelman Journal: J Am Heart Assoc Date: 2020-02-28 Impact factor: 5.501
Authors: Monirah A Albabtain; Maha M Alharthi; Khalid Dagriri; Amr A Arafat; Esraa Ayrout; Yahya Alhebaishi; Ahmed AlFagih Journal: Saudi Med J Date: 2020-11 Impact factor: 1.484